



Centre for
Public Health

Merseyside Inter Agency Drug Misuse Database

January– March 2007

Sefton DAAT

Quarter 4 2006/07

**Esther Shepherd, Martin Chandler,
Jim McVeigh**

DRAFT REPORT

The final version will be available on the IAD website

www.cph.org.uk/iad

Acknowledgements:

The Authors would like to thank the following for their valuable contributions to the production of this report: Paul Duffy, Adam Marr, Simon Russell and Claire Shaw.

We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts:

Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
Castle House
North Street
L3 2AY

(0151) 231 4531

m.chandler@ljmu.ac.uk

Esther Shepherd

IAD Researcher

(0151) 231 4521

e.shepherd@ljmu.ac.uk

www.cph.org.uk/iad

Contents

	<u>Page</u>
Introduction	1
Arrest Referral	3
Table 1: Individuals assessed, by Gender and Age Group	
Table 2: Year to Date, by Gender and Age Group	
Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Probation	5
Syringe Exchange Services	6
Agency	
Table 4: Individuals by Gender	
Table 5: Individuals by Gender: Steroid Users omitted	
Table 6: Individuals by Age Group	
Table 7: Individuals by Age Group: Steroid Users omitted	
Table 8: Gender by Age Group of Individuals	
Table 9: Gender by Age Group: Steroid Users omitted	
Table 10: Year to Date, by Gender & Age Group	
Table 11: Year to Date, by Gender & Age Group: Steroid Users omitted	
Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender	
Table 13: Main Drug of Use, for New Agency Syringe Exchange Clients, by Age Group	
Pharmacy	11
Table 14: Individuals by Gender	
Table 15: Individuals by Age Group	
Table 16: Year to Date, by Gender & Age Group	
Combined	12
Table 17: Individuals in Syringe Exchange, by Gender	
Table 18: Individuals in Syringe Exchange, by Gender: Steroid Users omitted	
Table 19: Individuals in Syringe Exchange, by Age Group	
Table 20: Individuals in Syringe Exchange, by Age Group: Steroid Users omitted	
Table 21: Year to Date, by Gender & Age Group	
Table 22: Total Syringes Provided	

National Drug Treatment Monitoring System (NDTMS) 14

Table 23: Individuals in contact with Treatment Services, by Gender

Table 24: Year to Date, by Gender

Table 25: Individuals in contact with Treatment Services, by Age Group

Table 26: Year to Date, by Age Group

Table 27: Ethnicity of Individuals in Contact with Treatment Services

Table 28: Individuals in contact with Treatment Services, by Main Drug of Use

Connexions 17

Table 29: Individuals in Contact with Connexions, by Gender

Table 30: Year to Date, by Gender

Table 31: Individuals in Contact with Connexions, by Age

Table 32: Year to Date, by Age

Table 33: Individuals in Contact with Connexions by Drug/Alcohol Problem

Table 34: Year to Date, by Drug/Alcohol Problem

Combined Datasets 19

Table 35: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Table 36: Year to Date, by Gender & Age Group

Cross Matched Datasets 20

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.


To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.



The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)**Quarter 4 (2006/07)****Introduction**

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	97	78.9
Female	26	21.1
Age Group		
Under 18	0	0
18-19	17	13.8
20-24	20	16.3
25-29	18	14.6
30-34	20	16.3
35-39	25	20.3
40-44	17	13.8
45+	6	4.9
Total	123	100

Table 2: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	0	0	0	0	0	0
18-19	35	10.9	2	2.4	37	9.2
20-24	68	21.3	9	10.8	77	19.1
25-29	53	16.6	11	13.3	64	15.9
30-34	60	18.8	29	34.9	89	22.1
35-39	59	18.4	17	20.5	76	18.9
40-44	30	9.4	11	13.3	41	10.2
45+	15	4.7	4	4.8	19	4.7
Total	320	100	83	100	403	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	0	0
Benzodiazepines	1	0
Cannabis	9	5
Crack	37	21
Cocaine	3	16
Ecstasy	1	0
Heroin	56	9
Methadone	5	0
Other	1	0

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

PROBATION

Quarter 4 (2006/07)

Introduction

Due to last minute technical problems it was not possible to include Probation data for this quarter. The Annual Report will however, include data from Quarter 4 2006/07.

SYRINGE EXCHANGE SERVICES

Quarter 4 (2006/07)

Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY SYRINGE EXCHANGE

Table 4: Individuals by Gender

New Clients	n	%
Male	36	83.7
Female	7	16.3
<i>Total</i>	<i>43</i>	<i>100</i>
All Clients		
Male	196	86.3
Female	31	13.7
<i>Total</i>	<i>227</i>	<i>100</i>

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	17	77.3
Female	5	22.7
<i>Total</i>	<i>22</i>	<i>100</i>
All Clients		
Male	142	83.0
Female	29	17.0
<i>Total</i>	<i>171</i>	<i>100</i>

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	2	4.7	7	3.1
20-24	6	14.0	18	7.9
25-29	11	25.6	36	15.9
30-34	8	18.6	45	19.8
35-39	10	23.3	64	28.2
40-44	3	7.0	32	14.1
45+	3	7.0	25	11.0
Total	43	100	227	100

Table 7: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	0	0	2	1.2
20-24	0	0	5	2.9
25-29	4	18.2	24	14.0
30-34	6	27.3	36	21.1
35-39	7	31.8	56	32.7
40-44	3	13.6	27	15.8
45+	2	9.1	21	12.3
Total	22	100	171	100

Table 8: Gender by Age Group of Individuals

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0	0	0
18-19	6	3.1	1	3.2
20-24	17	8.7	1	3.2
25-29	34	17.3	2	6.5
30-34	39	19.9	6	19.4
35-39	54	27.6	10	32.3
40-44	26	13.3	6	19.4
45+	20	10.2	5	16.1
Total	196	100	31	100

Table 9: Gender by Age Group: Steroid Users omitted

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0	0	0
18-19	2	1.4	0	0
20-24	4	2.8	1	3.4
25-29	23	16.2	1	3.4
30-34	30	21.1	6	20.7
35-39	46	32.4	10	34.5
40-44	21	14.8	6	20.7
45+	16	11.3	5	17.2
Total	142	100	29	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	1	0.2	1	1.2	2	0.3
18-19	17	3.0	1	1.2	18	2.8
20-24	70	12.5	5	6.2	75	11.7
25-29	111	19.8	12	14.8	123	19.1
30-34	90	16.0	19	23.5	109	17.0
35-39	158	28.1	24	29.6	182	28.3
40-44	64	11.4	11	13.6	75	11.7
45+	51	9.1	8	9.9	59	9.2
Total	562	100	81	100	643	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0	1	1.3	1	0.2
18-19	3	0.9	0	0	3	0.7
20-24	18	5.1	5	6.5	23	5.4
25-29	46	13.1	10	13.0	56	13.1
30-34	61	17.4	18	23.4	79	18.5
35-39	131	37.3	24	31.2	155	36.2
40-44	53	15.1	11	14.3	64	15.0
45+	39	11.1	8	10.4	47	11.0
Total	351	100	77	100	428	100

Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Heroin	14	38.9	4	57.1
Steroids	19	52.8	2	28.6
Unknown	3	8.3	1	14.3
Total	36	100	7	100

Please Note: Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 13: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

Age Group	Heroin		Steroids		Unknown	
	n	%	n	%	n	%
Under 18	0	0	0	0	0	0
18-19	0	0	2	100	0	0
20-24	0	0	6	100	0	0
25-29	3	27.3	7	63.6	1	9.1
30-34	6	75.0	2	25.0	0	0
35-39	6	60.0	3	30.0	1	10.0
40-44	1	33.3	0	0	2	66.7
45+	2	66.7	1	33.3	0	0
Total	18	41.9	21	48.8	4	9.3

* % Totals are by Drug, not Age Group

PHARMACY SYRINGE EXCHANGE

Table 14: Individuals by Gender

New Clients	n	%
Male	123	82.6
Female	26	17.6
<i>Total</i>	<i>149</i>	<i>100</i>
All Clients		
Male	362	84.6
Female	66	15.4
<i>Total</i>	<i>428</i>	<i>100</i>

Table 15: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	1	0.7	2	0.5
18-19	2	1.3	2	0.5
20-24	21	14.1	36	8.4
25-29	25	16.8	60	14.0
30-34	17	11.4	58	13.6
35-39	42	28.2	133	31.1
40-44	20	13.4	76	17.8
45+	21	14.1	61	14.3
<i>Total</i>	<i>149</i>	<i>100</i>	<i>428</i>	<i>100</i>

Table 16: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	2	0.2	1	0.6	3	0.3
18-19	11	1.2	0	0	11	1.0
20-24	94	10.2	10	5.8	104	9.5
25-29	143	15.5	32	18.5	175	15.9
30-34	139	15.0	39	22.5	178	16.2
35-39	260	28.1	39	22.5	299	27.2
40-44	160	17.3	40	23.1	200	18.2
45+	116	12.5	12	6.9	128	11.7
<i>Total</i>	<i>925</i>	<i>100</i>	<i>173</i>	<i>100</i>	<i>1098</i>	<i>100</i>

COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 17: Individuals in Syringe Exchange, by Gender

New Clients	n	%
Male	158	82.7
Female	33	17.3
<i>Total</i>	<i>191</i>	<i>100</i>
All Clients		
Male	531	85.0
Female	94	15.0
<i>Total</i>	<i>625</i>	<i>100</i>

Table 18: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted

New Clients	n	%
Male	18	78.3
Female	5	21.7
<i>Total</i>	<i>23</i>	<i>100</i>
All Clients		
Male	477	83.8
Female	92	16.2
<i>Total</i>	<i>569</i>	<i>100</i>

Table 19: Individuals in Syringe Exchange, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	1	0.5	2	0.3
18-19	4	2.1	9	1.4
20-24	27	14.1	53	8.5
25-29	35	18.3	92	14.7
30-34	25	13.1	98	15.7
35-39	52	27.2	185	29.7
40-44	23	12.0	103	16.5
45+	24	12.6	83	13.3
<i>Total</i>	<i>191</i>	<i>100</i>	<i>625</i>	<i>100</i>

Table 20: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	2	0.4
18-19	0	0	4	0.7
20-24	0	0	40	7.0
25-29	4	17.4	80	14.1
30-34	7	30.4	89	15.6
35-39	7	30.4	177	31.1
40-44	3	13.0	98	17.2
45+	2	8.7	79	13.9
Total	23	100	569	100

Table 21: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	3	0.2	2	0.8	5	0.3
18-19	28	2.0	1	0.4	29	1.8
20-24	159	11.3	11	4.6	170	10.4
25-29	242	17.3	40	16.9	282	17.2
30-34	215	15.3	56	23.6	271	16.5
35-39	382	27.2	60	25.3	442	27.0
40-44	214	15.3	48	20.3	262	16.0
45+	159	11.3	19	8.0	178	10.9
Total	1402	100	237	100	1639	100

Table 22: Total Syringes Provided

	This Quarter	Year to Date
Barrels	39,980	157,964
Needles	43,798	172,786

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)

Quarter 4 (2006/07)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 23: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	182	69.5
Female	80	30.5
<i>Total</i>	<i>262</i>	<i>100</i>
All Clients		
Male	1,130	70.3
Female	478	29.7
<i>Total</i>	<i>1,608</i>	<i>100</i>

Table 24: Year to Date, by Gender

New Clients	n	%
Male	607	70.3
Female	257	29.7
<i>Total</i>	<i>864</i>	<i>100</i>
All Clients		
Male	1353	69.5
Female	593	30.5
<i>Total</i>	<i>1,946</i>	<i>100</i>

Table 25: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	8	3.1	68	4.2
18-19	6	2.3	29	1.8
20-24	22	8.4	89	5.5
25-29	23	8.8	160	10.0
30-34	55	21.0	298	18.5
35-39	78	29.8	467	29.0
40-44	44	16.8	322	20.0
45+	26	9.9	175	10.9
Total	262	100	1,608	100

Table 26: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	66	7.6	115	5.9
18-19	13	1.5	35	1.8
20-24	77	8.9	206	10.6
25-29	111	12.8	293	15.1
30-34	182	21.1	441	22.7
35-39	208	24.1	480	24.7
40-44	130	15.0	231	11.9
45+	77	8.9	145	7.5
Total	864	100	1,946	100

Table 27: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	253	96.6	1,568	97.5
White Irish	1	0.4	4	0.3
Other White	1	0.4	7	0.4
White & Black Caribbean	0	0	1	0.1
White & Black African	2	0.8	4	0.3
Other Mixed	0	0	2	0.1
Other Asian	0	0	1	0.1
African	1	0.4	2	0.1
Other Black	1	0.4	3	0.2
Other	0	0	13	0.8
Unknown	3	1.1	3	0.2
Total	262	100	1608	100

Table 28: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	180	68.7	1,113	69.2
Methadone	14	5.3	78	4.9
Other Opiates	5	1.9	19	1.2
Benzodiazepine	0	0	8	0.5
Amphetamines	3	1.2	17	1.1
Cocaine	32	12.2	134	8.3
Crack	6	2.3	23	1.4
Ecstasy	1	0.4	4	0.2
Cannabis	21	8.0	135	8.4
Solvents	0	0	1	0.1
Anti-depressants	0	0	2	0.1
Other/Unknown	0	0	74	4.6
Total	262	100	1608	100

CONNEXIONS

Quarter 4 (2006/07)

Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

Table 29: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	38	70.4
Female	16	29.6
Total	54	100

Table 30: Year to Date, by Gender

Gender	n	%
Male	58	65.9
Female	30	34.1
Total	88	100

Table 31: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	15	27.8
17	15	27.8
18	13	24.1
19	11	20.4
Total	54	100

Table 32: Year to Date, by Age

Age Group	n	%
16	27	30.7
17	23	26.1
18	20	22.7
19	18	20.5
Total	88	100

Table 33: Individuals in Contact with Connexions by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	11	20.4
Drugs	43	79.6
Total	54	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

Table 34: Year to Date, by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	22	25.0
Drugs	66	75.0
Total	88	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

COMBINED DATASETS

Quarter 4 (2006/07)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 35: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	1604	73.9
Female	567	26.1
Age Group		
Under 18	116	5.3
18-19	71	3.3
20-24	214	9.9
25-29	300	13.8
30-34	422	19.4
35-39	560	25.8
40-44	299	13.8
45+	189	8.7
Total	2171	100

Table 36: Year to Date, by Gender and Age Group

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	122	4.4	41	5.0	163	4.6
18-19	111	4.0	21	2.5	132	3.7
20-24	336	12.3	81	9.8	417	11.7
25-29	448	16.3	125	15.2	573	16.1
30-34	508	18.5	187	22.7	695	19.5
35-39	645	23.5	196	23.8	841	23.6
40-44	338	12.3	108	13.1	446	12.5
45+	234	8.5	65	7.9	299	8.4
Total	2742	100	824	100	3566	100

CROSS-MATCHED DATASETS

Quarter 4 (2006/07)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets




Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

